200 related articles for article (PubMed ID: 35512565)
1. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
2. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
3. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity.
Stimson L; Rowlands MG; Newbatt YM; Smith NF; Raynaud FI; Rogers P; Bavetsias V; Gorsuch S; Jarman M; Bannister A; Kouzarides T; McDonald E; Workman P; Aherne GW
Mol Cancer Ther; 2005 Oct; 4(10):1521-32. PubMed ID: 16227401
[TBL] [Abstract][Full Text] [Related]
4. Small molecule modulators of histone acetyltransferase p300.
Balasubramanyam K; Swaminathan V; Ranganathan A; Kundu TK
J Biol Chem; 2003 May; 278(21):19134-40. PubMed ID: 12624111
[TBL] [Abstract][Full Text] [Related]
5. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
7. Histone acetyl transferases as emerging drug targets.
Dekker FJ; Haisma HJ
Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
[TBL] [Abstract][Full Text] [Related]
8. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.
Balasubramanyam K; Varier RA; Altaf M; Swaminathan V; Siddappa NB; Ranga U; Kundu TK
J Biol Chem; 2004 Dec; 279(49):51163-71. PubMed ID: 15383533
[TBL] [Abstract][Full Text] [Related]
9. Is histone acetylation the most important physiological function for CBP and p300?
Bedford DC; Brindle PK
Aging (Albany NY); 2012 Apr; 4(4):247-55. PubMed ID: 22511639
[TBL] [Abstract][Full Text] [Related]
10. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
Gou P; Zhang W
Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
12. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
13. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation.
Park S; Stanfield RL; Martinez-Yamout MA; Dyson HJ; Wilson IA; Wright PE
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5335-E5342. PubMed ID: 28630323
[TBL] [Abstract][Full Text] [Related]
14. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
15. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors.
Sagar V; Zheng W; Thompson PR; Cole PA
Bioorg Med Chem; 2004 Jun; 12(12):3383-90. PubMed ID: 15158807
[TBL] [Abstract][Full Text] [Related]
16. Assays for Validating Histone Acetyltransferase Inhibitors.
Waddell AR; Liao D
J Vis Exp; 2020 Aug; (162):. PubMed ID: 32831305
[TBL] [Abstract][Full Text] [Related]
17. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H
J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866
[TBL] [Abstract][Full Text] [Related]
18. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
19. Characterization of novel inhibitors of histone acetyltransferases.
Eliseeva ED; Valkov V; Jung M; Jung MO
Mol Cancer Ther; 2007 Sep; 6(9):2391-8. PubMed ID: 17876038
[TBL] [Abstract][Full Text] [Related]
20. Multiple roles for acetylation in the interaction of p300 HAT with ATF-2.
Karanam B; Wang L; Wang D; Liu X; Marmorstein R; Cotter R; Cole PA
Biochemistry; 2007 Jul; 46(28):8207-16. PubMed ID: 17590016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
